Dr. Philip A. Lowry
Claim this profileGuthrie Medical Group PC-Robert Packer Hospital
Studies Lung Cancer
Studies Breast Cancer
17 reported clinical trials
61 drugs studied
Area of expertise
1Lung Cancer
Stage II
Stage I
Stage III
2Breast Cancer
Stage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Philip A. Lowry is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
More about Philip A. Lowry
Clinical Trial Related6 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Philip A. Lowry has experience with
- Nivolumab
- Ipilimumab
- Paclitaxel
- Dabrafenib Mesylate
- Carboplatin
- Orelabrutinib (ICP-022)
Breakdown of trials Philip A. Lowry has run
Lung Cancer
Breast Cancer
Breast cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Philip A. Lowry specialize in?
Philip A. Lowry focuses on Lung Cancer and Breast Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage I.
Is Philip A. Lowry currently recruiting for clinical trials?
Yes, Philip A. Lowry is currently recruiting for 4 clinical trials in Sayre Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Philip A. Lowry has studied deeply?
Yes, Philip A. Lowry has studied treatments such as Nivolumab, Ipilimumab, Paclitaxel.
What is the best way to schedule an appointment with Philip A. Lowry?
Apply for one of the trials that Philip A. Lowry is conducting.
What is the office address of Philip A. Lowry?
The office of Philip A. Lowry is located at: Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania 18840 United States. This is the address for their practice at the Guthrie Medical Group PC-Robert Packer Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.